CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 36 enrolled
Drug / intervention
Varenicline +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02681510
NCT02681510Phase 4Completed
CompareCT.gov

UW-CTRI Smoking Cessation Medication Tolerability Study

University of Wisconsin, Madison·interventional·Posted Feb 12, 2016·Updated Oct 11, 2017

In Brief

A Phase 4 clinical trial evaluating Varenicline, Nicotine Transdermal Patch, and 1 other intervention for Smoking. Completed, enrolled 36 participants across 1 site.

Detailed Summary

This study will focus on enhancing future smoking cessation treatment effectiveness by piloting a potentially more powerful combination of three FDA-approved pharmacotherapies: varenicline plus combination of two types of nicotine replacement therapy (NRT) treatment (nicotine lozenge and nicotine patch). Data from this pilot study will help inform the design of future studies that would use this combination treatment as a cessation tool within the chronic care arsenal of treatments.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSmoking
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20162017201820192020202120222023202420252026
First PostedFeb 12, 2016
Enrollment StartFeb 1, 2016
Primary CompletionJun 13, 2016
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 10.4 years ago

Interventions

Vareniclinedrug

Standard FDA approved 12 weeks of treatment with Varenicline

Nicotine Transdermal Patchdrug

Standard FDA approved 12 weeks of treatment with Nicotine Transdermal Patch

Nicotine Minidrug

Standard FDA approved 12 weeks of treatment with Nicotine Mini-Lozenge